LeMaitre Vascular (NSDQ:LMAT) said it will pay $4.6 million for Neovasc‘s (NYSE:NVC) XenoSure vascular patch, used to repair blood vessels.
LeMaitre Vascular pays $5M for Neovasc’s XenoSure | Wall Street Beat
neovasc
St. Jude Medical wins CE Mark, launches Enlightn renal denervation system | MassDevice.com On Call
MASSDEVICE ON CALL —St. Jude Medical (NYSE:STJ) landed CE Mark approval and announced commercial launch for its Enlightn renal denervation system as a treatment for hypertension.
Zimmer slides on Q1 results | Earnings Roundup
Diabetes: Medtronic wins clearance for next-gen clinical continuous glucose monitor | Regulatory Roundup
Medtronic Inc. (NYSE:MDT) won FDA clearance for its next generation iPro2 Professional continuous glucose monitor.
The iPro2 Professional is a clinician-owned device that collects glucose data from a sensor inserted into a patient’s skin.
The device tracks the patient’s glucose levels for 3 days, collecting data as many as 288 times each day. The information may provide insight into how diet, medication and daily activities affect a patient’s glucose levels.
